The Patent Finder

Alteogen, Inc.

14 patents currently held · Updated Nov 22, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Oct 2031
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 9, 2026
    The maintenance fee for Novel ALPHA-1 Antitrypsin Variant, Preparation Method Thereof and Use Thereof (US 9,051,395) comes due Dec 9, 2026. Unpaid by Jun 9, 2027, it lapses early.
  • 1 fee due Jul 9, 2027
    The maintenance fee for Antibody specifically binding to FOLR1 and uses thereof (US 11,866,492) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
  • 1 fee due Nov 14, 2027
    The maintenance fee for Growth hormone receptor antagonists and fusion proteins thereof (US 11,981,719) comes due Nov 14, 2027. Unpaid by May 15, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,012,606In Vivo Half Life Increased Fusion Protein or Peptide Maintained by Sustained in Vivo Release, and Method for Increasng in Vivo Half-Life Using Same
In force
 · High confidence
In forceHigh confidence
US 9,051,395Novel ALPHA-1 Antitrypsin Variant, Preparation Method Thereof and Use Thereof
In force
 · High confidence
In forceHigh confidence
US 9,814,782Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same
In force
 · USPTO record
In forceUSPTO record
US 9,902,753Method of purifying a long-acting human growth hormone
In force
 · USPTO record
In forceUSPTO record
US 9,982,032Stable liquid formulation of fusion protein with IgG Fc domain
In force
 · USPTO record
In forceUSPTO record
US 12,090,210Antibody-drug conjugate comprising modified antibody
In force
 · USPTO record
In forceUSPTO record
US 11,414,476Method for Producing Fusion Protein Having Igg FC Domain
In force
 · High confidence
In forceHigh confidence
US 11,235,065Antibody-drug conjugate comprising modified antibody
In force
 · USPTO record
In forceUSPTO record
US 11,981,719Growth hormone receptor antagonists and fusion proteins thereof
In force
 · USPTO record
In forceUSPTO record
US 11,866,492Antibody specifically binding to FOLR1 and uses thereof
In force
 · USPTO record
In forceUSPTO record
10 of 14 patents shown.
Pro members see all 14.
Pro members: see all 14 patents
Also on record, not counted in the 14: 2 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

8 pending · 1 no status recorded

Showing 1 to 9 of 9, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
19/231,008Novel Hyaluronidase Variants and Pharmaceutical Composition Containing the SameJun 6, 2025Pending
18/940,159Method for Producing Recombinant HyaluronidaseNov 7, 2024Pending
18/940,064Method for Producing Recombinant HyaluronidaseNov 7, 2024Pending
18/721,629N-terminal and/or C-terminal Cleaved Soluble PH20 Polypeptide and Use ThereofJun 21, 2023Pending
18/705,496Pharmaceutical Composition Comprising Human Hyaluronidase PH20 and DrugOct 28, 2022Pending
18/702,881Method for Purifying Fusion Protein Having Igg FC DomainOct 18, 2022Pending
17/859,466Method for Producing Fusion Protein Having Igg FC DomainJul 7, 2022Pending
17/744,575Pharmaceutical Composition for Subcutaneous Administration Containing Human Hyaluronidase PH20 Variant and DrugMay 13, 2022Pending
15/393,365Dec 29, 2016No status recorded
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited